drugset / Trial / NCT00656630
Medication Development in Alcoholism: Acamprosate Versus Naltrexone
Phase 2
Completed
68 enrolled
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupTriple-blindOther
Summary
The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
Timeline
- Start
- 2007-12
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acamprosate | Small molecule | 666 mg | — |
| Comparator | Naltrexone | Small molecule | 50 mg | — |